Bacterial strain as agents for preventing and/or treating respiratory disorders
The invention relates to a novel bacterial strain deposited with the CNCM under number 1-4969. This strain has properties that are useful in the treatment of respiratory disorders. The invention also relates to compositions and uses of said strain.
1. A freeze-dried composition comprising an Enterococcus sp. strain deposited with the Collection nationale des cultures de microorganismes (CNCM, 25 rue du Docteur Roux, 75724 Paris Cedex 15, France) under number 1-4969.
2. The composition of claim 1 , wherein the strain is inactivated.
3. The composition of claim 2 , wherein the strain is heat-inactivated.
4. The composition of claim 2 , wherein the strain is present in the form of an extract.
5. A composition comprising an Enterococcus sp. strain deposited with the Collection nationale des cultures de microorganisms (CNCM, 25 rue du Docteur Roux, 75724 Paris Cedex 15, France) under number 1-4969 and at least one antifungal or antibacterial agent.
6. The composition of claim 5 , wherein the strain is inactivated.
7. The composition of claim 6 , wherein the strain is heat-inactivated.
8. The composition of claim 6 , wherein the strain is present in the form of an extract.
9. A method for the treatment and/or reduction of the development of one or more respiratory diseases comprising administering a pharmaceutical composition comprising an Enterococcus sp. strain deposited with the Collection nationale des cultures de microorganismes (CNCM, 25 rue du Docteur Roux, 75724 Paris Cedex 15, France) under number 1-4969 and at least one pharmaceutically acceptable excipient to a patient in need therefor.
10. The method according to claim 9 , wherein the expression of TH2 cytokines is not increased or is decreased in a patient treated with said strain relative to a patient not treated with said strain.
11. The method of claim 9 , wherein the treated patient is a child.
12. The method of claim 9 , wherein the strain comprised in the composition is inactivated.
13. The method of claim 12 , wherein the strain comprised in the composition is heat inactivated.
14. The method of claim 12 , wherein the strain is present in the form of an extract.
15. The method of claim 10 , wherein the strain comprised in the composition is inactivated.
16. The method of claim 15 , wherein the strain comprised in the composition is heat inactivated.
17. The method of claim 16 , wherein the strain is present in the form of an extract.
18. The method according to claim 10 , wherein the treated patient is a child.
19. The method according to claim 12 , wherein the treated patient is a child.
20. The method according to claim 13 , wherein the treated patient is a child.
21. The method according to claim 14 , wherein the treated patient is a child.
22. The method of claim 9 , wherein said respiratory disease is selected from asthma; bronchitis; infectious bronchitis; eosinophilic bronchitis; chronic obstructive pulmonary disease (COPD); chronic obstructive bronchopneumopathy; cystic fibrosis; pulmonary fibrosis; cryptogenic fibrosing alveolitis; idiopathic pulmonary fibrosis; interstitial idiopathic pneumonias; fibrosis complicating anti-neoplastic therapy; chronic infection; tuberculosis; aspergillosis; fungal infection; complications of lung transplantation; vasculitis; thrombotic disorders of the pulmonary vascular system; pulmonary hypertension; pulmonary arterial hypertension; chronic cough associated with inflammatory and secretory respiratory tract conditions; iatrogenic cough; acute rhinitis; chronic rhinitis; drug-induced rhinitis; vasomotor rhinitis; perennial allergic rhinitis; seasonal allergic rhinitis; hay fever; nasal polyposis; acute viral infection; cold common colds; infection due to respiratory syncytial virus, influenza, coronavirus, severe acute respiratory syndrome (SARS) or adenovirus; pulmonary oedema; pulmonary embolism; pneumonia; pulmonary sarcoidosis; silicosis; farmer's lung; hypersensitivity pneumonitis; respiratory failure; acute respiratory distress syndrome; emphysema; chronic bronchitis; tuberculosis or lung cancer.
23. The method of claim 22 , wherein said asthma is selected from bronchial asthma, allergic asthma, intrinsic asthma, extrinsic asthma, exercise-induced asthma, drug-induced asthma, dust-induced asthma, or steroid-resistant asthma.